Sensorium Therapeutics
Jeffrey Brown has over 18 years of experience in the biotechnology industry. Jeffrey began their career in 2003 as a Post-Doctoral Fellow at the Boston University School of Medicine. In 2006, they moved to Pfizer as a Principal Scientist, where they investigated mechanisms of action for novel antidepressant and neuropsychiatric medications. In 2007, they joined Bristol-Myers Squibb as a Sr. Research Investigator and in 2016 they moved to Alexion Pharmaceuticals, Inc. as a Research Scientist. In 2017, they joined Wave Life Sciences as Director CNS Biology, where they managed external research collaboration with Takeda and internal CNS discovery efforts. In 2019, they moved to Voyager Therapeutics, Inc. as Sr. Director of Neuroscience and in 2021 they joined Deep Genomics as Vice President of Preclinical Research. In 2022, they became the CEO and Founder of Scientific Foundation LLC, a Biotech Consulting Company, and a Board Member of the Huntington's Disease Society of America. Currently, they are the Chief Scientific Officer at Sensorium Therapeutics.
Jeffrey Brown received a Bachelor of Science (BS) in Biology, General from Colby-Sawyer College in 1995. Jeffrey then attended the University of Utah, where they earned a Ph.D. in Pharmacology / Toxicology in 2001. Currently, they are enrolled in an Executive MBA program at Suffolk University, studying Business Administration and Management, General.